Circulating Biomarkers for Diagnosis, Prognosis and Treatment Response Prediction in Cancer Patients, Part B delves into the crucial role of circulating biomarkers in cancer diagnosis and treatment monitoring. Specific chapters in this new release include Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers, Identification of circulating biomarkers for cancer therapy-related cardiovascular toxicity, Extracellular Vesicles as Dynamic Biomarkers: Monitoring Therapeutic Responses and Drug Resistance in Cancer, and more.This comprehensive work explores the various types of biomarkers, their significance in early cancer detection, prognostication, and evaluation of therapeutic responses. It covers cutting-edge research on circulating tumor cells, cell-free DNA, exosomes, and other biomarkers that can revolutionize cancer management. Additionally, it discusses the challenges, advancements, and future prospects of utilizing circulating biomarkers in personalized cancer care. - Provides a comprehensive overview of circulating biomarkers used in cancer diagnosis, prognosis, and treatment response monitoring - Discusses the clinical utility of circulating biomarkers in early cancer detection, prognostication, treatment selection, and monitoring therapeutic responses - Explores the latest technologies and methodologies for the detection, quantification, and analysis of circulating biomarkers in cancer patients